Testing an experimental HIV vaccine for safety in healthy adults
This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must be in good general health, with no major medical conditions that could affect your safety or the trial results.
- You must be HIV negative and willing to discuss HIV prevention and get counseling.
- You must not have previously received an experimental HIV vaccine (unless you got a placebo, which is okay).
- You must not have had certain heart conditions like myocarditis or pericarditis, or a bleeding disorder requiring special precautions.
- You must agree to use effective contraception if you can become pregnant, and not get pregnant or breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
This trial tests an experimental HIV vaccine in healthy adults, including those living with HIV. The goal is to see if the vaccine is safe and prompts an immune response.
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.